Safety Reading Notes

Read safety context beside the research guide.

The PPAR-gamma source set includes safety-context rows around 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 33522084

Mechanistic research summary: mechanistic or pharmacological (1)

PubMed For Dummies Article

PPAR-gamma Evidence Review: the long-form source walk-through

Quick read
  • PPAR-gamma currently has 21 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 33522084
  • The evidence classes most visible in the row language are insufficient (16), and mechanistic or pharmacological (5). PMID 30405366
  • The study-design language most visible in the row language is Narrative or expert review (12), Animal study (3), and Cellular or in vitro study (3). PMID 41545891
  • The repeated topics are receptor, target, or pharmacology mechanisms (3), nausea-related or inflammation-related outcomes (2), Endocannabinoids and endocannabinoid-like lipids research topics (2), safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (2), and other mapped categories (12), which tells the reader where to start opening PubMed and DOI links. PMID 32798553

Start with the research question

PPAR-gamma is built from 21 source-backed evidence row(s) and 17 research source(s). The current evidence classes read as insufficient (16), and mechanistic or pharmacological (5), and the study-design language most often reads as Narrative or expert review (12), Animal study (3), and Cellular or in vitro study (3). PMID 33522084

The row-level question is not simply whether PPAR-gamma is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, target, or pharmacology mechanisms (3), nausea-related or inflammation-related outcomes (2), Endocannabinoids and endocannabinoid-like lipids research topics (2), safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (2), and other mapped categories (12). PMID 19833407

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 42076122

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 39657242

Mechanistic evidence 5 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 42212209

Limits and uncertainty 19 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 19833407

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 17704824

Where this page has the most source density

The largest bucket surfaced for this page is receptor, target, or pharmacology mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Endocannabinoids and endocannabinoid-like lipids, which gives readers another way to see what the literature repeatedly circles. PMID 33522084

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 19833407

Bucket chapters: what the literature is circling

receptor, target, or pharmacology mechanisms

3 research sources 3 rows (253-256) Mapped evidence with interpretation limits: insufficient (3)

PPAR-gamma appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 33522084

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 33522084

  • Evidence row 253

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084

  • Evidence row 256

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, o... PMID 42212209

Endocannabinoids and endocannabinoid-like lipids

2 research sources 2 rows (293-294) Mapped evidence with interpretation limits: insufficient (2)

PPAR-gamma appears in rows studying Endocannabinoids and endocannabinoid-like lipids. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 19833407

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 19833407

  • Evidence row 293

    THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; o... PMID 19833407

  • Evidence row 294

    THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; o... PMID 17704824

nausea-related or inflammation-related outcomes

2 research sources 2 rows (125-146) Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)

PPAR-gamma appears in rows studying nausea-related or inflammation-related outcomes. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41545891

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 41545891

  • Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome m... PMID 41545891

  • Evidence row 146

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or infla... PMID 32798553

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

1 research source 1089 Mechanistic research summary: mechanistic or pharmacological (1)

PPAR-gamma appears in rows studying 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36481187

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 36481187

  • Evidence row 1089

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (outcome measure: 2-AG biology, receptor pharmacology, metabolism, phys... PMID 36481187

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

1 research source 1063 Mapped evidence with interpretation limits: insufficient (1)

PPAR-gamma appears in rows studying anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36150527

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 36150527

  • Evidence row 1063

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 36150527

Appetite and metabolic outcomes

1 research source 622 Mapped evidence with interpretation limits: insufficient (1)

PPAR-gamma appears in rows studying Appetite and metabolic outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 42105814

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 42105814

  • Evidence row 622

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight,... PMID 42105814

GPR55

1 research source 935 Mapped evidence with interpretation limits: insufficient (1)

PPAR-gamma appears in rows about GPR55 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 35083862

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 35083862

  • Evidence row 935

    CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharma... PMID 35083862

Inflammation-related outcomes

1 research source 71 Mapped evidence with interpretation limits: insufficient (1)

PPAR-gamma appears in rows studying Inflammation-related outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41545891

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 41545891

  • Evidence row 71

    CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammatio... PMID 41545891

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (5 row(s)), and safety/tolerability context (3 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 33522084

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 19833407

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 42352060
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 42105814
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 32315173

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 33522084

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 19833407

Source-reading checklist for PPAR-gamma

  1. Open the linked PubMed or DOI record. PMID 35083862
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 40684872
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 36150527
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 36481187
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 25995819

Source Notes

PPAR-gamma source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 44

    THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological (outcome measure: safety, effect, or mechanism claims). PMID 30405366

    Evidence class: mechanistic or pharmacological. Source: Cannabis Therapeutics and the Future of Neurology.
  2. Evidence row 70

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  3. Evidence row 71

    CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  4. Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  5. Evidence row 146

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 32798553

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Behavioural and molecular effects of cannabidiolic acid in mice.
  6. Evidence row 242

    Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 42076122

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.
  7. Evidence row 253

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084

    Evidence class: insufficient; Study design: Animal study. Source: Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.
  8. Evidence row 255

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 39657242

    Evidence class: insufficient; Study design: Narrative or expert review. Source: A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.
  9. Evidence row 256

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 42212209

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: Pharmaceutical formulations and biomedical applications.
  10. Evidence row 293

    THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 19833407

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.
  11. Evidence row 294

    THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 17704824

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
  12. Evidence row 558

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
  13. Evidence row 571

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 42105814

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.
  14. Evidence row 622

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 42105814

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.
  15. Evidence row 648

    CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
  16. Evidence row 676

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 32315173

    Evidence class: mechanistic or pharmacological. Source: The Oxidation of Phytocannabinoids to Cannabinoquinoids.
  17. Evidence row 935

    CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35083862

    Evidence class: insufficient; Study design: Narrative or expert review. Source: A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).
  18. Evidence row 983

    CBD modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 40684872

    Evidence class: insufficient; Study design: Animal study. Source: Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.
  19. Evidence row 1063

    Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36150527

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.
  20. Evidence row 1089

    2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36481187

    Evidence class: mechanistic or pharmacological. Source: Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b.
  21. Evidence row 1139

    NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 25995819

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells.